← Eichor
Study identifier: NCT06311162 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Early Life Intervention in Pediatrics Supported by E-health - SMOKE

Condition: Smoking Reduction · Asthma in Children · Wheezing  ·  Sponsor: Insel Gruppe AG, University Hospital Bern

PhaseNA
Planned participants160
Who can joinAll sexes, N/A to 5 Years
Healthy volunteersYes

About this study

Unrestricted parental smoking habits are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of non-communicable diseases (NCDs). Exposure to secondhand tobacco smoke in early life contributes to the development of specific NCDs in children, i.e. asthma. Early preventive measures to improve lifestyle behavior in parents are therefore of utmost importance. The aim of ELIPSE-II is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering levels of urinary cotinine as a measure of second-hand smoke exposure in their children .

This description comes directly from the study's public registry record.

Talk to the study team

Matthias V. Kopp, Prof. Dr.  ·  +41 31 66 4 13 51  ·  matthias.kopp@insel.ch

Julian Jakob, Dr.  ·  +41 31 632 12 93  ·  julian.jakob@insel.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Paediatrics, Inselspital, Bern University HospitalBern, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06311162